---
schema_version: "secwatch.filing_event.v1"
accession: "0001730463-24-000076"
form_type: "8-K"
ticker: "AUTL"
cik: "0001730463"
company_name: "Autolus Therapeutics plc"
filed_at: "2024-06-28T23:59:59+00:00"
generated_at: "2026-06-01T00:42:57.795201+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.25
calibrated_materiality_score: 0.15
confidence: "high"
source: SEC EDGAR
---

# Autolus Therapeutics shareholders approve all nine resolutions at 2024 AGM

## Summary
- Adoption of 2023 annual accounts passed with 190.78M votes for, 35.8K against.
- Directors' remuneration report approved: 167.10M for, 23.69M against.
- Ernst & Young LLP reappointed as auditors for the coming year.
- All four director re-elections passed: Bain (99.52%), Butitta (98.36%), Itin (99.83%), Young (99.12%).
- Board authorized to allot shares up to $8,400 nominal value (Resolution 8) and disapply pre-emption rights (Resolution 9).

## SEC filing metadata
- accession: 0001730463-24-000076
- form_type: 8-K
- ticker: AUTL
- cik: 0001730463
- company_name: Autolus Therapeutics plc
- filed_at: 2024-06-28T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.25
- calibrated_materiality_score: 0.15
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1730463/000173046324000076/0001730463-24-000076-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1730463/000173046324000076/autl-20240628.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001730463-24-000076
- JSON: https://secwatch.observer/filing/0001730463-24-000076.json
- Plain text: https://secwatch.observer/filing/0001730463-24-000076.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.